The current approaches of numerous monoclonal antibodies (mAbs) targeting the immune checkpoints PD-1/PD-L1 and CTLA-4 are different as they reactivate a pre-existing anti-tumor immunity. This evidence concerns the gene CTLA4 and neoplasm.